Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178741 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL29376536 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL119481 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL30055069 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL25358998 | 0.94 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL31398353 | 0.94 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL31398346 | 0.94 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL31689003 | 0.93 | MDM2 (0.50) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL29398655 | 0.92 | TLR2 (0.48) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL14417867 | 0.91 | CASP3 (0.46) | MDM4TP53TLR2CASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496356-A | CXCR4 specific molecular imaging probe and preparation method and application thereof | 上海交通大学医学院附属仁济医院 | 2023-07-28 | — | — | CN | claimed |
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | disclosed |
| EP-4704904-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | Tambo, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4667019-A1 | PSMA-TARGETED RADIOPHARMACEUTICAL, AND SYNTHESIS AND USE THEREOF | Norroy Bioscience Co., Ltd. (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-31 | — | — | US | disclosed |
| WO-2025089217-A1 | COMPOUND FOR USE AS SUBSTRATE FOR EVALUATING ACTIVITY OF γ-D-GLUTAMYL-L-LYSYL ENDOPEPTIDASE | 株式会社ヤクルト本社 | 2025-05-01 | — | — | WO | disclosed |
| WO-2025070731-A1 | PEPTIDEPEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025070720-A1 | PEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| EP-4511384-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | Provincial Health Services Authority (CA) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024229427-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| CN-116496356-A | CXCR4 specific molecular imaging probe and preparation method and application thereof | 上海交通大学医学院附属仁济医院 | 2023-07-28 | — | — | CN | disclosed |
| CN-116457028-A | Novel CXCR4 targeting compounds | 省卫生服务机构 | 2023-07-18 | — | — | CN | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11629171-B2 | Beta-hairpin peptidomimetics | SPEXIS AG (CH) | 2023-04-18 | — | — | US | disclosed |
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220218852-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-07-14 | — | — | US | disclosed |
| WO-2022082312-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-04-28 | — | — | WO | disclosed |
| CN-114401732-A | CD38 binding agents and uses thereof | 克莱奥药品有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114364690-A | Novel radiolabeled CXCR4 targeting compounds for diagnosis and therapy | 省卫生服务机构 | 2022-04-15 | — | — | CN | disclosed |
| EP-3956346-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | Provincial Health Services Authority (CA) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | CXCR4, CXCL12, ACKR3 | MDM4 4337/4885TP53 1252/4885TLR2 1494/4885 |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | MDM4 1295/4885TP53 822/4885TLR2 2870/4885 |
| US-20220218852-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | CXCR4, CXCR1, FPR1 | MDM4 4011/4885TP53 2939/4885TLR2 440/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | MDM4 3817/4885TP53 1733/4885TLR2 489/4885 |
| US-11629171-B2 | Beta-hairpin peptidomimetics | POLL, POLQ, HBZ | MDM4 2103/4885TP53 222/4885TLR2 3053/4885 |
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | CD38, CD47, CD2 | MDM4 1651/4885TP53 121/4885TLR2 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.